Tags

Type your tag names separated by a space and hit enter

Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.
Vaccine. 2015 Dec 16; 33(51):7307-7314.V

Abstract

BACKGROUND AND OBJECTIVES

We assessed monovalent rotavirus (RV1) vaccine effectiveness (VE) in a high-income setting with RV1 predominant use, and examined the burden of pediatric rotavirus gastroenteritis following the implementation of an RV1-only vaccination program.

METHODS

We conducted active rotavirus gastroenteritis surveillance among children 8 weeks to <3 years of age at three hospitals. Participant information and vaccination histories were collected via parent/guardian interview and medical records. Stool specimens were tested for rotavirus; positive specimens were genotyped. The effect of increasing RV1 coverage on rotavirus prevalence was examined as a weekly time series via binomial regression with a log link function, using either categorical season or mean 2-dose rotavirus seasonal vaccine coverage as the exposure variable. As compared with RV1 vaccine formulation, rotavirus genotypes were classified as homotypic, partly-heterotypic, or heterotypic; prevalence of each was compared by season. A test-negative case-control design was used to examine RV1 VE against hospitalization or emergency visits.

RESULTS

We enrolled 866 participants in active surveillance; of these, 384 (44.3%) were eligible for VE analyses. After adjustment for season, we detected a 70.1% (95% CI: 21.9%, 88.6%) relative decrease in rotavirus prevalence in the 2013-14 season compared with 2012-13 season. On average, a 1% increase in ≥2-dose rotavirus coverage among children 1 year of age was associated with a 3.8% (95% CI: 1.8%, 5.8%) relative decrease in rotavirus prevalence. Rotavirus homotypic strain prevalence decreased, with 77% (95% CI: 68%, 89%) versus 8% (95% CI: 0%, 36%) prevalence during the 2011-12 and 2013-14 seasons, respectively. Adjusted 2-dose RV1 VE was 91.2% (95% CI: 61.6%, 98.0%).

CONCLUSIONS

RV1 vaccine was highly effective to prevent rotavirus hospitalizations and emergency visits among children <3 years of age in a high-income setting with its predominant use. Our estimates were similar to high-income settings with concurrent RV1 and pentavalent vaccine use.

Authors+Show Affiliations

McGill University, Montreal, QC, Canada.McGill University, Montreal, QC, Canada.McGill University, Montreal, QC, Canada.Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.Sainte-Justine University Hospital, Montreal, QC, Canada.Laboratoire de santé publique du Quebec (LSPQ), Sainte-Anne-de-Bellevue, Montreal, QC, Canada.McGill University, Montreal, QC, Canada; The Montreal Children's Hospital, Montreal, QC, Canada. Electronic address: caroline.quach@mcgill.ca.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26546262

Citation

Doll, Margaret K., et al. "Effectiveness of Monovalent Rotavirus Vaccine in a High-income, Predominant-use Setting." Vaccine, vol. 33, no. 51, 2015, pp. 7307-7314.
Doll MK, Buckeridge DL, Morrison KT, et al. Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting. Vaccine. 2015;33(51):7307-7314.
Doll, M. K., Buckeridge, D. L., Morrison, K. T., Gagneur, A., Tapiero, B., Charest, H., & Quach, C. (2015). Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting. Vaccine, 33(51), 7307-7314. https://doi.org/10.1016/j.vaccine.2015.10.118
Doll MK, et al. Effectiveness of Monovalent Rotavirus Vaccine in a High-income, Predominant-use Setting. Vaccine. 2015 Dec 16;33(51):7307-7314. PubMed PMID: 26546262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting. AU - Doll,Margaret K, AU - Buckeridge,David L, AU - Morrison,Kathryn T, AU - Gagneur,Arnaud, AU - Tapiero,Bruce, AU - Charest,Hugues, AU - Quach,Caroline, Y1 - 2015/11/03/ PY - 2015/09/11/received PY - 2015/10/16/revised PY - 2015/10/18/accepted PY - 2015/11/8/entrez PY - 2015/11/8/pubmed PY - 2016/10/7/medline KW - Effectiveness KW - Rotavirus KW - Vaccination SP - 7307 EP - 7314 JF - Vaccine JO - Vaccine VL - 33 IS - 51 N2 - BACKGROUND AND OBJECTIVES: We assessed monovalent rotavirus (RV1) vaccine effectiveness (VE) in a high-income setting with RV1 predominant use, and examined the burden of pediatric rotavirus gastroenteritis following the implementation of an RV1-only vaccination program. METHODS: We conducted active rotavirus gastroenteritis surveillance among children 8 weeks to <3 years of age at three hospitals. Participant information and vaccination histories were collected via parent/guardian interview and medical records. Stool specimens were tested for rotavirus; positive specimens were genotyped. The effect of increasing RV1 coverage on rotavirus prevalence was examined as a weekly time series via binomial regression with a log link function, using either categorical season or mean 2-dose rotavirus seasonal vaccine coverage as the exposure variable. As compared with RV1 vaccine formulation, rotavirus genotypes were classified as homotypic, partly-heterotypic, or heterotypic; prevalence of each was compared by season. A test-negative case-control design was used to examine RV1 VE against hospitalization or emergency visits. RESULTS: We enrolled 866 participants in active surveillance; of these, 384 (44.3%) were eligible for VE analyses. After adjustment for season, we detected a 70.1% (95% CI: 21.9%, 88.6%) relative decrease in rotavirus prevalence in the 2013-14 season compared with 2012-13 season. On average, a 1% increase in ≥2-dose rotavirus coverage among children 1 year of age was associated with a 3.8% (95% CI: 1.8%, 5.8%) relative decrease in rotavirus prevalence. Rotavirus homotypic strain prevalence decreased, with 77% (95% CI: 68%, 89%) versus 8% (95% CI: 0%, 36%) prevalence during the 2011-12 and 2013-14 seasons, respectively. Adjusted 2-dose RV1 VE was 91.2% (95% CI: 61.6%, 98.0%). CONCLUSIONS: RV1 vaccine was highly effective to prevent rotavirus hospitalizations and emergency visits among children <3 years of age in a high-income setting with its predominant use. Our estimates were similar to high-income settings with concurrent RV1 and pentavalent vaccine use. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/26546262/Effectiveness_of_monovalent_rotavirus_vaccine_in_a_high_income_predominant_use_setting_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)01574-1 DB - PRIME DP - Unbound Medicine ER -